Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of antilipemic agents on HDL subfractions in type 2 diabetes with hyperlipidemia
ChiCTR-TRC-10001059Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of atorvastatin, fenofibrate and acipimox in hyperlipidemia and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Serum lipids and HDL subfractions. Started Oct 2009; status: completed.
02
Drugs
atorvastatinfenofibrateacipimox
03
Conditions
hyperlipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-10001059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001059.